Basel Medical Group Ltd Ordinary Shares (BMGL) Financial Ratios
4 years of historical data (2021–2024) · Healthcare · Medical - Healthcare Plans
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
2.88
↓-58% vs avg
5yr avg: 6.87
30Y Low6.9·High6.9
ROE
↓
-194.6%
↑-1002% vs avg
5yr avg: -17.7%
30Y Low-195%·High53%
Debt/EBITDA
↓
N/A
—
5yr avg: 2.57
30Y Low1.6·High3.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BMGL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Basel Medical Group Ltd Ordinary Shares currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $11M | $33M | — | — | — |
| Enterprise Value | $11M | $34M | — | — | — |
| P/E Ratio → | -1.74 | — | — | — | — |
| P/S Ratio | 1.24 | 2.95 | — | — | — |
| P/B Ratio | 2.88 | 6.87 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BMGL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | 2.99 | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
BMGL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Basel Medical Group Ltd Ordinary Shares earns an operating margin of -19.3%. Operating margins have compressed from 20.6% to -19.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -194.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | 77.7% | 77.7% | 77.6% | 75.9% | 79.6% |
| Operating Margin | -19.3% | -19.3% | 21.8% | 20.6% | 23.2% |
| Net Profit Margin | -106.8% | -106.8% | 20.6% | 18.4% | 18.6% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -194.6% | -194.6% | 31.8% | 38.8% | 53.4% |
| ROA | -72.9% | -72.9% | 13.1% | 11.1% | 11.7% |
| ROIC | -21.5% | -21.5% | 15.4% | 12.6% | 15.1% |
| ROCE | -28.5% | -28.5% | 24.3% | 21.6% | 25.6% |
BMGL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $440393 ($3M total debt minus $3M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | 0.70 | 0.70 | 0.57 | 1.31 | 2.74 |
| Debt / EBITDA | — | — | 1.57 | 2.82 | 3.33 |
| Net Debt / Equity | — | 0.09 | 0.31 | 1.09 | 2.32 |
| Net Debt / EBITDA | — | — | 0.86 | 2.34 | 2.82 |
| Debt / FCF | — | — | 0.93 | 2.31 | 3.18 |
| Interest Coverage | -60.32 | -60.32 | 14.64 | 9.93 | 8.44 |
BMGL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.23x means Basel Medical Group Ltd Ordinary Shares can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.28x to 1.23x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 1.23 | 1.23 | 2.26 | 2.28 | 2.18 |
| Quick Ratio | 1.19 | 1.19 | 2.25 | 2.27 | 2.17 |
| Cash Ratio | 0.28 | 0.28 | 0.27 | 0.19 | 0.22 |
| Asset Turnover | — | 0.67 | 0.62 | 0.63 | 0.63 |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
BMGL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Basel Medical Group Ltd Ordinary Shares does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $2M | $1M | $1M | $1M |
Peer Comparison
Compare BMGL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BMGLYou | $11M | -1.7 | — | — | 77.7% | -19.3% | -194.6% | -21.5% | — |
 ACMR | $7B | 74.2 | 49.8 | — | 44.4% | 12.1% | 6.2% | 7.0% | 2.4 |
 CLOV | $3B | -30.6 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
 HCAI | $8M | -0.2 | — | — | 6.2% | -322.7% | -262.3% | -71.3% | — |
 SGBX | $32963 | -0.0 | — | — | -4.9% | -195.0% | — | -62569.3% | — |
 MD | $2B | 12.5 | 9.1 | 8.0 | 24.7% | 12.1% | 20.3% | 14.8% | 2.6 |
 AMSF | $610M | 13.1 | 9.2 | 68.4 | 46.4% | 18.6% | 18.5% | 21.9% | 0.0 |
 PRVA | $3B | 136.2 | 59.3 | 19.0 | 9.9% | 1.6% | 3.1% | 9.9% | 0.2 |
 ALHC | $4B | -5862.2 | 92.7 | 39.2 | 12.4% | 0.4% | -0.5% | — | 7.5 |
 DOCS | $4B | 21.3 | 17.2 | — | 89.1% | 33.3% | 19.3% | 19.8% | 0.0 |
 MCK | $92B | 20.0 | 13.5 | 16.1 | 3.6% | 1.6% | — | 254.1% | 1.2 |
| Healthcare Median | — | 22.5 | 14.3 | 19.1 | 63.6% | -4.8% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BMGL — Frequently Asked Questions
Quick answers to the most common questions about buying BMGL stock.
What is Basel Medical Group Ltd Ordinary Shares's P/E ratio?
Basel Medical Group Ltd Ordinary Shares's current P/E ratio is -1.7x. This places it at the 50th percentile of its historical range.
What is Basel Medical Group Ltd Ordinary Shares's ROE?
Basel Medical Group Ltd Ordinary Shares's return on equity (ROE) is -194.6%. The historical average is -17.7%.
Is BMGL stock overvalued?
Based on historical data, Basel Medical Group Ltd Ordinary Shares is trading at a P/E of -1.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Basel Medical Group Ltd Ordinary Shares's profit margins?
Basel Medical Group Ltd Ordinary Shares has 77.7% gross margin and -19.3% operating margin.